Dataset Information

Antibody Characterisation using FFAP

ABSTRACT: Modern therapeutic approaches, especially for cancer and certain autoimmune disorders, evolved and have started to frequently rely on monoclonal antibodies (mAb) or other recombinantly prepared biomolecules (biopharmaceuticals) instead of on small molecules. The mAb treatment is effective but comes at a high financial cost. That is why there is a high demand to develop and market so-called ‘biosimilars’, which are highly similar to already approved biopharmaceuticals.The major hindrance for biosimilars manufacturers is that they must declare and prove an almost identical structure, biological activity, quality, safety and efficacy that apply to the original innovator molecule. To prove structural identity, it’s necessary to characterize not only primary sequences and post-translational modification of expressed proteins but also proper protein folding, and any chemical modifications introduced by production, purification and long-term storage. To determine higher order structure of antibodies, a broad palette of techniques can be considered. In this project we used recently discovered fast fluor-alkylation of proteins (FFAP) that offers another approach for structural characterization of therapeutic antibodies and identifying epitope-paratope interacting regions.

INSTRUMENT(S): timsTOF SCP

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Zdenek Kukacka

LAB HEAD: Petr Novak

PROVIDER: PXD044326 | Pride | 2024-05-21

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 88

Publications

Structural Characterization of Monoclonal Antibodies and Epitope Mapping by FFAP Footprinting.

Fojtík Lukáš L Kalaninová Zuzana Z Fiala Jan J Halada Petr P Chmelík Josef J Man Petr P Kukačka Zdeněk Z Novák Petr P

Analytical chemistry 20240502 19

Covalent labeling in combination with mass spectrometry is a powerful approach used in structural biology to study protein structures, interactions, and dynamics. Recently, the toolbox of covalent labeling techniques has been expanded with fast fluoroalkylation of proteins (FFAP). FFAP is a novel radical labeling method that utilizes fluoroalkyl radicals generated from hypervalent Togni reagents for targeting aromatic residues. This report further demonstrates the benefits of FFAP as a new metho ...[more]

PMID: 38698660

Similar Datasets

Project description:CD24 is a potential oncogene reported to be overexpressed in a large variety of human malignancies. We have shown that CD24 is overexpressed in 90% of colorectal tumors at a fairly early stage in the multistep process of carcinogenesis. Anti-CD24 monoclonal antibodies (mAb) induce a significant growth inhibition in colorectal and pancreatic cancer cell lines that express the protein. This study is designed to investigate further the effects of CD24 down-regulation using mAb or small interfering RNA in vitro and in vivo. Western blot analysis showed that anti-CD24 mAb induced CD24 protein down-regulation through lysosomal degradation. mAb augmented growth inhibition in combination with five classic chemotherapies. Xenograft models in vivo showed that tumor growth was significantly reduced in mAb-treated mice. Similarly, stable growth inhibition of cancer cell lines was achieved by down-regulation of CD24 expression using short hairpin RNA (shRNA). The produced clones proliferated more slowly, reached lower saturation densities, and showed impaired motility. Most importantly, down-regulation of CD24 retarded tumorigenicity of human cancer cell lines in nude mice. Microarray analysis revealed a similar pattern of gene expression alterations when cells were subjected to anti-CD24 mAb or shRNA. Genes in the Ras pathway, mitogenactivated protein kinase, or BCL-2 family and others of oncogenic association were frequently down-regulated. As a putative new oncogene that is overexpressed in gastrointestinal malignancies early in the carcinogenesis process, CD24 is a potential target for early intervention in the prevention and treatment of cancer. The study compared gene expression profiles between human CRC cells HT29 before and after expression of 1 and 2 shRNA vectors directed at the human CD24 gene, GFP control gene, HT29 cells and Colo357, human pancreatic cancer cells, before and after the inhibition of the CD24 molecule using 72h treatment with anti-CD24 monoclonal antibodies.

			Action	DRS
	Ab_IMAc_1_24915.d.zip	Other
	Ab_IMAc_2_24916.d.zip	Other
	Ab_IMAc_3_24917.d.zip	Other
	Ab_TAc_1_24912.d.zip	Other
	Ab_TAc_2_24913.d.zip	Other